Cargando…
Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial
BACKGROUND: Patients with extensive-stage small-cell lung cancer (ES-SCLC) have a particularly poor prognosis. And the treatment options for patients with relapsed or refractory ES-SCLC are limited. Thus, we conducted an open-label, multicenter, single-arm phase II clinical trial to assess the effic...
Autores principales: | He, Zhen, Zhou, Hanqiong, Wang, Junsheng, Li, Ding, Zhang, Xudong, Wang, Pengyuan, Ma, Tianjiang, Zhang, Yueqiang, Tian, Chuntao, Chen, Yunfang, Zou, Minglei, Han, Yu, Xu, Cong, Ma, Shuxiang, Wang, Lili, Wu, Xuan, Chen, Gongbin, Wang, Qiming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947412/ https://www.ncbi.nlm.nih.gov/pubmed/33718030 http://dx.doi.org/10.21037/tlcr-20-1235 |
Ejemplares similares
-
A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer
por: Hu, Nanlin, et al.
Publicado: (2021) -
Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial
por: He, Zhen, et al.
Publicado: (2022) -
Apatinib in the treatment of gastric cancer in Henan Province: a multicenter prospective real-world observational study (Ahead-HAP01)
por: Ma, Yijie, et al.
Publicado: (2022) -
Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
por: Wang, Fen, et al.
Publicado: (2020) -
EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
por: Hou, Jiabao, et al.
Publicado: (2022)